The Association Between Metabolic Syndrome and Prostate Cancer Risk: A Large-Scale Investigation and Study of Chinese

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Jun 7

PMID 35669684

Authors

Xiaoshuai Gao

Ruicen Li

Tao Jin

Huairong Tang

Affiliations

Soon will be listed here.

Abstract

Background: To investigate the association between metabolic syndrome (MetS) and its components and prostate cancer (PCa).

Methods: This study enrolled 482 943 consecutive men who underwent routine health checkups at the Health Management Center of West China Hospital Between 2010 and 2017. For patients with elevated prostate-specific antigen (PSA) levels or color Doppler ultrasound indicating abnormal prostates, we recommended prostate puncture and follow-up. We used the chi-square test and independent t-test for categorical variables and continuous variables, respectively. We used logistic regression analysis to evaluate the effects of MetS and its components on prostate cancer risk.

Results: We found that the incidence of PCa in Chinese men over 40 years of age was 0.1%. Among the 85882 participants, 31.5% (27016/85882) of the patients were diagnosed with MetS. PCa was associated with older age, higher PSA levels, lighter weight and shorter height, hypertension, elevated fasting blood glucose (FBG) and HDL cholesterol level, lower triglycerides. After excluded the interference of other factors in multivariate logistic analysis, we found that MetS, hypertension, hyperlipidemia, hyperglycemia, and obesity were not related to the risk of PCa. High age and PSA levels were risk factors for prostate cancer.

Conclusions: High age and PSA levels were risk factors for prostate cancer. MetS, hypertension, hyperlipidemia, hyperglycemia, and obesity were not related to the risk of PCa.

Citing Articles

Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders.

Pagoni M, Zogopoulos V, Kontogiannis S, Tsolakou A, Zoumpourlis V, Tsangaris G Cancer Genomics Proteomics. 2025; 22(2):285-305.

PMID: 39993800 PMC: 11880924. DOI: 10.21873/cgp.20502.

Association between the metabolic score for insulin resistance and prostate cancer: a cross-sectional study in Xinjiang.

Wang J, Apizi A, Tao N, An H PeerJ. 2024; 12:e17827.

PMID: 39076779 PMC: 11285359. DOI: 10.7717/peerj.17827.

Role of Metabolism and Metabolic Pathways in Prostate Cancer.

Wanjari U, Mukherjee A, Gopalakrishnan A, Murali R, Dey A, Vellingiri B Metabolites. 2023; 13(2).

PMID: 36837801 PMC: 9962346. DOI: 10.3390/metabo13020183.

References

Bhindi B, Locke J, Alibhai S, Kulkarni G, Margel D, Hamilton R . Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2014; 67(1):64-70. DOI: 10.1016/j.eururo.2014.01.040. View

Ibrahim Y, Yee D . Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res. 2004; 14(4):261-9. DOI: 10.1016/j.ghir.2004.01.005. View

Neil Thomas G, Ho S, Janus E, Lam K, Hedley A, Lam T . The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract. 2005; 67(3):251-7. DOI: 10.1016/j.diabres.2004.07.022. View

Morote J, Ropero J, Planas J, Bastaros J, Delgado G, Placer J . Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2012; 111(7):1031-6. DOI: 10.1111/j.1464-410X.2012.11406.x. View

Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino M, Rafaniello C . Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause. 2013; 20(12):1301-9. DOI: 10.1097/GME.0b013e31828ce95d. View

Lindkvist B, Almquist M, Bjorge T, Stocks T, Borena W, Johansen D . Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer Causes Control. 2012; 24(1):107-16. DOI: 10.1007/s10552-012-0096-6. View

Ford E, Li C, Zhao G . Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010; 2(3):180-93. DOI: 10.1111/j.1753-0407.2010.00078.x. View

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

Sfanos K, De Marzo A . Prostate cancer and inflammation: the evidence. Histopathology. 2012; 60(1):199-215. PMC: 4029103. DOI: 10.1111/j.1365-2559.2011.04033.x. View

10.

Zhang G, Zhu Y, Dong D, Han C, Gu C, Gu W . The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy. Asian J Androl. 2015; 17(5):839-44. PMC: 4577601. DOI: 10.4103/1008-682X.148138. View

11.

Beebe-Dimmer J, Nock N, Neslund-Dudas C, Rundle A, Bock C, Tang D . Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology. 2009; 74(1):185-90. PMC: 2704922. DOI: 10.1016/j.urology.2009.03.013. View

12.

Center M, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O . International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61(6):1079-92. DOI: 10.1016/j.eururo.2012.02.054. View

13.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

14.

Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B . The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):2088-96. PMC: 2923431. DOI: 10.1158/1055-9965.EPI-10-0112. View

15.

Powell I, Bollig-Fischer A . Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol. 2013; 27(6):879-91. PMC: 5415277. DOI: 10.1210/me.2013-1039. View

16.

Lund Haheim L, Wisloff T, Holme I, Nafstad P . Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006; 164(8):769-74. DOI: 10.1093/aje/kwj284. View

17.

Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R . Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005; 174(3):827-34. DOI: 10.1097/01.ju.0000169490.78443.59. View

18.

Harding J, Sooriyakumaran M, Anstey K, Adams R, Balkau B, Briffa T . The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?. Diabetes Metab. 2015; 41(6):463-9. DOI: 10.1016/j.diabet.2015.04.006. View

19.

Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino M, Parretta E . Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013; 36(2):132-9. DOI: 10.1007/BF03346748. View

20.

Laukkanen J, Laaksonen D, Niskanen L, Pukkala E, Hakkarainen A, Salonen J . Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004; 13(10):1646-50. View